What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?
Authors:
- Dharam J. KumbhaniDKDharam J. Kumbhani
- Thomas J. HeltonTHThomas J. Helton
- Deepak L. BhattDBDeepak L. Bhatt
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Drug-eluting stents: an early systematic review to inform policy*1, *2European Heart Journal, 2004
- Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary LesionsCirculation, 2004
- One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS StentCirculation, 2004
- Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary StentCirculation, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation, 2003
- A Paclitaxel-Eluting Stent for the Prevention of Coronary RestenosisNew England Journal of Medicine, 2003
- TAXUS ICirculation, 2003
- Coronary restenosis elimination with a sirolimus eluting stent; First European human experience with 6-month angiographic and intravascular ultrasonic follow-upEuropean Heart Journal, 2001
- Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary ArteriesCirculation, 2001